| DiViNe project–GSK: vaccine purification technology, 201609 collab GSK Italy is partner in Horizon 2020 project led by iBET |
2016-09-01 |
| DiViNe project–iBET (PT): vaccine purification technology, 201609 collab GenIbet + iBET are partners in Horizon 2020 project led by iBET |
2016-09-01 |
| DiViNe project–Merck (DE): vaccine purification technology, 201609– collab Merck is partner in Horizon 2020 project led by iBET |
2016-09-01 |
| Innovative Medicines Initiative–Lipotype: lipidomics, 201609– collab Lipotype is participant in RHAPSODY project on type 2 diabetes |
2016-09-01 |
| Phagenesis–Nestlé: investment, 201609– acquisition €na staged + milestone-based by Nestlé Health Science |
2016-09-01 |
| Rigontec–Germany (govt): business development, 201609– supply service support in US with German Accelerator Life Sciences programme |
2016-09-01 |
| Roche–Horizon Discovery: reference standards, 201609– collab developm + commercialisation of IHC Reference Standards with Ventana |
2016-09-01 |
| Zinsser Analytic–Kohlberg Kravis Roberts: investment, 201609 acquisition of ILS Gmbh + Zinsser Analytic GmbH from Mr+Ms Zinsser by Gardner Denver |
2016-09-01 |
| SPEware–Tecan: investment, 201608–201609 acquisition of SPEware for $50m in cash + $10m milestones |
2016-08-31 |
| Boehringer–Saniona: schizophrenia drugs, 201608– collab reserach €5m upfront + €85m milestones + royalties to identify compounds for schizophrenia |
2016-08-29 |
| Cyprotex–Danaher: mass spectrometer, 201608 supply two AB Sciex TripleTOF 6600 systems, one with Eksigent MicroLC + IonDrive + SWATH |
2016-08-25 |
| Cyprotex–Waters: mass spectrometer, 201608 supply existent of Xevo G2-XS QTof MS system used for mass metabolite identification studies |
2016-08-25 |
| Denali Therapeutics–F-Star: antibody technology, 201608– collab r+d bispecific antibodies for drug delivery across blood-brain barrier |
2016-08-25 |
| Earlybird–SEVERAL: investment, 201608 first closing of Earlybird Health Tech Fund incl investors NRW.Bank + Generali + Miele + BMWE + Barmer GEK |
2016-08-24 |
| Ayoxxa–Märzhäuser: microplate reader, 201608 collab developm + contract manufacturing of Ayoxxa Reader AR01 by Märzhäuser |
2016-08-22 |
| InterHealth Nutraceuticals–Lonza: investment, 201608–201609 acquisition of InterHealth for up to $300m in upfront + earn-out from Kainos Capital |
2016-08-15 |
| Mologen–NN: business development services, 201608c– supply service to find outlicensing opportunities for lefitolimod |
2016-08-11 |
| Oculis–SEVERAL: investment, 201608 financing round Series A led by Brunnur Ventures + Silfurberg |
2016-08-11 |
| Thermo Fisher–Hamilton: liquid handling products, 201608– direct non-excl distribution of automation products for forensics in EMEA + China |
2016-08-11 |
| Werfen–Protagen: biomarker, 201608– license semi-excl for use of BICD2 biomarker for diagnosis of systemic sclerosis to Inova Diagnostics |
2016-08-11 |
| Gilead–Polyphor: drug discovery, 201608– collab + license agreem identifying + optimise drug candidates using macrocycle platform |
2016-08-10 |
| Akvolution–High-Tech Gründerfonds: investment, 201608 financing round Series A incl returning investor HTGF |
2016-08-04 |
| Akvolution–SEVERAL: investment, 201608 financing round Series A from HTGF + VNG Innovation + Bamag + private investors |
2016-08-04 |
| Oncgnostics–SEVERAL: investment, 201608–201606 crowdfunding campaign €500k via Seedmatch platform |
2016-08-04 |
| Arcus Biosciences–SEVERAL: investment, 201608 2nd financing round $70m led by new investor GV plus new + all existing investors |
2016-08-01 |
| ViraTherapeutics–Boehringer: investment, 201809 acquisition of all remaining shares of ViraTby BI with total transaction value of €210m |
2016-08-01 |
| Applied Micorarrays–Scienion: print/spotting technology, 201607– collab strategic partnership to support developm + production of IVD products |
2016-07-28 |
| Merck (DE)–Amoy Diagnostics: molecular diagnostics, 201607– collab developm liquid biopsy RAS biomarker CRC test based on ADx-SuperARMS for China |
2016-07-28 |
| Eurofins–Lablicate: mass spectrometry software, 201607 supply existent Eurofins is reference customer for OpenChrom s/w |
2016-07-27 |
| Symrise–Lablicate: mass spectrometry software, 201607 supply existent Symrise is reference customer for OpenChrom s/w |
2016-07-27 |
| Lophius–SEVERAL: investment, 201607 financing round €4.25m led by VRD GmbH + incl Bayern Kapital + Wolf Biotech + WIC GmbH |
2016-07-26 |
| Numares–Bavaria (govt): investment, 201607 financing round incl €2m from Wachstumsfonds Bayern managed by Bayern Kapital |
2016-07-26 |
| Numares–SEVERAL: investment, 201607 financing round incl €2m from Wachstumsfonds Bayern managed by Bayern Kapital |
2016-07-26 |
| InflaRx–SEVERAL: investment, 201607 financing round Series C €31m incl new investor Staidson Hongkong Investment Co Ltd |
2016-07-21 |
| Molecular Health–Akampion: public relations, 201607 service existent EMEA media + investor relations by Akampion |
2016-07-21 |
| Relypsa–Galenica: investment, 201607–201609 acquisition $1.53b cash tender offer $32/share |
2016-07-21 |
| Jounce Therapeutics–Nextech Invest: investment, 201607 existent investment of Nextech Oncology Fund IV |
2016-07-20 |
| Kura Oncology–Nextech Invest: investment, 201607 existent investment of Nextech Oncology Fund IV |
2016-07-20 |
| Nextech Invest–SEVERAL: investment, 201607 final closing of $64m Oncology Fund IV with Limited Partners in US + Europe + Asia |
2016-07-20 |
| Peloton Therapeutics–Nextech Invest: investment, 201607 existent investment of Nextech Oncology Fund IV |
2016-07-20 |
| ViroCyt–Sartorius: investment, 201607 acquisition valueing ViroCyt at $16m |
2016-07-15 |
| Boehringer–Univ Dundee: PROTAC technology, 201607– collab developm of PROTACs |
2016-07-14 |
| Pro Farma–Recordati: investment, 201607 acquisition CHF16m 100% of Pro Farma AG by Recordati |
2016-07-14 |
| RedoxTherapies–Juno Therapeutics: investment, 201607 acquisition $10m cash + milestones of RedoxTherapies by Juno |
2016-07-14 |
| Bayer–X-Chem: small-molecule drug discovery, 2016– collab extension of access to DEX technology up to $528m in upfront + r+d funding + milestones |
2016-07-12 |
| Delenex–Cell Medica: investment, 201607 acquisition €na of Delenex Pharmaceuticals AG by Cell Medica |
2016-07-12 |
| Valneva–EU (govt): credit, 201607 EIB RnD loan up to €25m in tranches within 24-months period to advance vaccine programs |
2016-07-12 |
| AMSilk–Kirchhoff Consult: public relations, 201607 service existent by Kirchhoff Consult AG |
2016-07-11 |
| AMSilk–SEVERAL: investment, 201607 financing round with existing investors MIG Fonds + AT Newtec |
2016-07-11 |
| Antibiotic Research UK–Evotec: drug discovery services, 201607– collab research €na to discovery antibiotic resistance breakers (ARBs) |
2016-07-11 |
| GenePOC–Debiopharm: investment, 201607 acquisition of majority share by acquiring all shares from Emerillon Capital + others |
2016-07-11 |
| Thomson Reuters–Onex Corp: investment, 201607–201610 acquisition $3.55b in cash of Thomson Reuters IP + Science business by Onex + Baring PE Asia |
2016-07-11 |
| CryoTherapeutics–Creathor Ventures: investment, 201607 financing round Series B totalling €5.2m incl lead investor Creathor Venture |
2016-07-07 |
| CryoTherapeutics–Germany (govt): investment, 201607 financing round Series B totalling €5.2m incl returning co-investor KfW |
2016-07-07 |
| CryoTherapeutics–Getz Brothers: investment, 201607 financing round Series B totalling €5.2m incl returning co-investor Getz Brothers |
2016-07-07 |
| CryoTherapeutics–High-Tech Gründerfonds: investment, 201607 financing round Series B totalling €5.2m incl returning co-investor HTGF |
2016-07-07 |
| CryoTherapeutics–North Rhine-Westphalia (govt): investment, 201607 financing round Series B totalling €5.2m incl returning co-investor NRW.Bank |
2016-07-07 |
| CryoTherapeutics–Peppermint: investment, 201607 financing round Series B totalling €5.2m incl returning co-investor Peppermint CBF |
2016-07-07 |
| CryoTherapeutics–SEVERAL: investment, 201607 financing round Series B €5.2m led by Creathor incl NRW.Bank + Peppermint CBF + HTGF et al |
2016-07-07 |
| Evotec–MIT: CRISPR technology, 201607– research tool license non-excl to CRISPR-Cas9 gene editing technology from Broad Institute |
2016-07-06 |
| kSep Systems–Sartorius: investment, 201607 acquisition $28m of kSep Holdings Inc by SSB |
2016-07-06 |
| Nicox–GHO Capital: investment, 201607– acquisition €26m with €9m cash + €12m shares+loan notes + €5m milestones of Nicox commercial operations by GHO |
2016-07-05 |
| Global Bioenergies–Germany (govt): grant, 201607–201709 BMBF grant €400k for developm of renewable gasoline additives |
2016-07-01 |
| Denali Therapeutics–SEVERAL: investment, 201606 financing round Series B $130m led by Baillie Gifford + incl all founding plus new investors |
2016-06-30 |
| PBM Capital–Lonza: investment, 201606 acquisition of Triangle Research Labs LLC from PBM Capital Group |
2016-06-30 |
| Charles River–Caprotec: CCMS technology, 201606 collab use of CCMS tech to identify protein targets relevant for phenotypic drug candidate responses |
2016-06-29 |
| Evotec–Ellersbrook: investment, 201606– Ellersbrook will invest in Evotec’s internal TargetNASH programme |
2016-06-29 |
| Evotec–Genedata: bioinformatics, 201606– supply license Evotec using Genedata Screener now in HTS + HCS |
2016-06-28 |
| IntelliCyt–Sartorius: investment, 201606 acquisition for $90m in cash incl $5m in future tax savings |
2016-06-28 |
| Novartis–Xencor: antibody technology, 201606– collab + license $150m upfront + cost-sharing developm of biospecific antibodies for cancer |
2016-06-28 |
| Storm Therapeutics–Merck (DE): investment, 201606 financing round Series A totalling £12m incl investor Merck Ventures |
2016-06-28 |
| Storm Therapeutics–SEVERAL: investment, 201606 financing round Series A £12m with CIC + Merck Ventures + Pfizer Venture + Touchstone Innovations |
2016-06-28 |
| Cosmo Pharmaceuticals–Paion: remimazolam, 201606– license excl €10m upfront + €42.5m milestones + royalties for developm + commercialisation in US |
2016-06-24 |
| CRISPR Therapeutics–SEVERAL: investment, 201606 financing round Series B additional $38m closing from new investors |
2016-06-24 |
| Paion–Cosmo Pharmaceuticals: investment, 201606 investment as part of license agreem w Cosmo becoming largest shareholder holding 9.09% |
2016-06-24 |
| IFM Therapeutics–Abingworth: investment, 201606 financing round Series A totalling $27m incl lead investors Atlas Venture + Abingworth |
2016-06-22 |
| IFM Therapeutics–Atlas Venture: investment, 201606 financing round Series A totalling $27m incl lead investors Atlas Venture + Abingworth |
2016-06-22 |
| IFM Therapeutics–Novartis: investment, 201606 financing round Series A totalling $27m incl co-investor Novartis |
2016-06-22 |
| IFM Therapeutics–SEVERAL: investment, 201606 financing round Series A $27m led by Atlas Venture + Abingworth + incl Novartis |
2016-06-22 |
| Qiagen–Barclays: financial services, 201606 supply financial advisor to Qiagen with regard to offer for Exiqon AS |
2016-06-22 |
| MetaSUB project–Qiagen: genomic sample preparation, 201606– collab project using Qiagen sample tech + library prepration workflows |
2016-06-21 |
| F2G Ltd–SEVERAL: investment, 201606 financing round $60m led by Sector Asset Management |
2016-06-20 |
| Allecra Therapeutics–Delos Capital: investment, 201606 financing round Series B totalling €22m incl new + lead investor Delos Capital |
2016-06-16 |
| Allecra Therapeutics–Forbion: investment, 201606 financing round Series B totalling €22m incl returning co-investor FCF II Co-Invest I fund |
2016-06-16 |
| Allecra Therapeutics–SEVERAL: investment, 201606 financing round Series B €22m led by new investor Delos Capital |
2016-06-16 |
| Gilde Investment–SEVERAL: investment, 201606 final close of €250m Gilde Healthcare IV fund incl cornernstone investor Philips |
2016-06-14 |
| Univ Manchester–Danaher: mass spectrometer, 201606 supply Sciex Lipidyzer Platform to Stoller Centre |
2016-06-13 |
| Bluebird Bio–Lonza: contract manufacturing, 201606– collab long-term commercial manufacturing of Lenti-D + LentiGlobin drug products by Lonza Houston |
2016-06-09 |
| CRISPR Therapeutics–Anagenesis: cell therapy, 201606– strategic collab + ww excl license to P2MC technology for cell therapy for muscle diseases |
2016-06-08 |
| Sony–Stratec: investment, 201606–201607 acquisition €30m 100% of Sony DADC BioSciences business by Stratec |
2016-06-08 |
| F-Star–CMC Biologics: contract manufacturing, 201606– service manufacturing of mAb² bispecific antibodies by CMC Biologics |
2016-06-07 |
| Dr. Falk Pharma–Cosmo Pharmaceuticals: antibiotic, 201606– license existent for Rifamycin SV MMX for EU + Australia |
2016-06-06 |
| Pieris–SEVERAL: investment, 201606 private placement $16.5m w 8.18m units (shares + warrants) at $2.015/unit led by BVF Partners |
2016-06-03 |
| Grünenthal–AstraZeneca: lesinurad, 201606– license excl for Europe + Latin America to Zurampic + fixed dose combi of lesinurad + allopurinol |
2016-06-02 |
| Thermo Fisher–908 Devices: sample separation technology, 201606 collab integration of ZipChip microfluidics separation with Orbitrap MS systems |
2016-06-02 |
| Boehringer–Harvard Univ: drug research, 201606– collab research alliance 3y €na for novel treatments for severe fibrotic diseases |
2016-06-01 |
| Emperra–Germany (govt): business development, 201606– supply service support in US with German Accelerator Life Sciences programme |
2016-06-01 |
| ERS Genomics–MacDougall Biomedical Communications: public relations, 201606 service existent by MacDougall |
2016-06-01 |
| TxCell–Univ Lübeck: cell therapy, 201606– collab €na developm of CAR-Treg cells to treat bullous pemphigoid with LIED |
2016-06-01 |
| Hyglos–Mérieux: investment, 201605 acquisition 100% of Hyglos by bioMérieux for €24m phased over 3 years |
2016-05-31 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lsus-life-sciences-usa-com.jpg)
1 2 3 ... 19 20 21 ... 53 54 55 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
